The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model

Journal of Periodontology

Volumn 71, Issue 10, 2000, Pages 1607-1612

  Yaffe, A ^a   Golomb, G ^c   Breuer, E ^c   Binderman, I ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE

Author keywords

Alendronate therapeutic use; Alveolar bone loss prevention and control; Animal studies; Bisphosphates therapeutic use; Comparison studies; Etidronate therapeutic use

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GELATIN SPONGE; ISA 13 1; PYROPHOSPHORIC ACID DERIVATIVE; SODIUM CHLORIDE; SUBEROIL BISPHOSPHONATE; UNCLASSIFIED DRUG; VS 5; VS 6;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MANDIBLE; MICRORADIOGRAPHY; MOUTH CAVITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RAT; SURGICAL TECHNIQUE; TONGUE;

EID: 0033736370     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2000.71.10.1607     Document Type: Article

References (23)

1. Wilderman MN. Repair after a periosteal retention procedure. J Periodontol 1963;34:487-503.
2. Pfeifer JS. The growth of gingival tissue over denuded bone. J Periodontol 1963;34:10-16.
3. Pfeifer JS. The reaction of alveolar bone to flap procedure in man. Periodontics 1965;3:135-140.
4. Tavtigan R. The height of facial radicular alveolar crest following apicaly positioned flap operation. J Periodontol 1970;41:412-418.
5. Wood DL, Hoag PM, Donnenfeld OW, Rosenberg DL. Alveolar crest reduction following full and partial thickness flaps. J Periodontol 1972;43:141-144.
6. Bragger CJ, Pasquali L, Korman KS. Remodeling of interdental alveolar bone after periodontal flap procedure assessed by means of computer-assisted densitometer image analysis (CADIA). J Clin Periodontol 1988;15:558-564.
7. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon (R.A.P) in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65:79-83.
8. Yaffe A, Fine N, Alt I, Binderman I. Effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 1995;66:999-1003.
9. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, Binderman I. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997;68:884-889.
10. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate on reducing alveolar bone loss, following periodontal surgery in rats. J Periodontol 2000; 71:1236-1240.
11. Adami S, Zamberlan M, Mian M, et al. Duration of the effect of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Min 1994;25: 75-82.
12. Liberman UA, Weiss SR, et al. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. New Engl J Med 1995; 333:1437-1443.
13. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
14. Sato M, Grasser W, Endo E, et al. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
15. 3H-etidronate in rat and mouse bones. Bone 1996;19:281-290.
16. Gallacher SJ. Bisphosphonates: role in treatment of corticosteroid-induced osteoporosis. Clin Immunother 1996; 6:154-162.
17. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Min Res 1990;5: 483-491.
18. Cohen H, Solomon V, Alferiev IS, Breuer E, et al. Bisphosphonates and tetracycline: experimental model for their evaluation in calcium-related disorders. Pharmacolog Res 1988;15:606-613.
19. Cohen H, Alferiev IS, Mönkkönen J, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine(isa-13-1)-a novel bisphosphonate. Pharm Res 1999;16:1401-1408.
20. Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G. Anticalcification and antiresorption effects of bisacylphosphonates. Bone 1995;16:511-520.
21. Yaffe A, Binderman I, Breuer E, Pinto T, Golomb G. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 1999;70:893-895.
22. Fleisch H. Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drug 1991;42:919-944.
23. Francis MD, Martodam RR. Chemical, biochemical, and medicinal properties of the diphosphonates. In: Hildebrand RL, ed. The Role of Phosphonates in Living Systems. Boca Raton, FL: CRC Press; 1983:55-96.